ID: 5417 | Pages: 145 | December 2017 | Region: Asia Pacific
The Asia Pacific Next Generation Antibody Therapeutics market size was around USD 600 million in 2017. It is expected to grow at a CAGR of 14.9% to reach USD 1.2 billion by 2022. It captures 20% of the global market.
Next generation antibody therapeutics have high efficiency and are more safe. Rapid advancements in monoclonal antibodies technology is the reason for this. These advances have improved bifunctional properties, decreased functional size along with immunogenicity. Several medical conditions like cancer; autoimmune diseases etc. are treated using these technologies because of its enhanced properties.
Rising number of cases of chronic diseases, rapid advancements in technology, higher investment in R&D and increasing healthcare expenditure are the primary drivers of market growth.
On the other hand, strict administrative guidelines and regulatory requirements and inordinate delays in approval for new drugs along with their high costs are the primary restraints of market growth.
The market is segmented by therapeutic application and by technology. Classification by therapeutic application entails Oncology and Autoimmune/Inflammatory Diseases. Classification by technology entails Antibody-Drug Conjugates (ADCs), Bispecific Antibodies (BsAbs), Fc Engineered Antibodies, Antibody Fragments and Antibody-like Proteins, and Biosimilar Antibody Products. Biosimilar antibody products in the technology segment accounted for the largest market share thereby dominating the market in the forecast period. Oncology sub-category in the therapeutics application market category captured largest market share and is expected to remain in the lead till 2022.
Classification by geography entails India, China, Korea, Japan and others. Asia Pacific is likely to be the fastest growing market with the highest CAGR in the forecast period. Economic boom in the emerging economies of India and China are the reasons for this.
Key players in the market include Roche, Seattle Genetics, Takeda, Dyax Corp., and Immunogen. Other players in the market include Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Technology
5.1.1 Introduction
5.1.2 Antibody-Drug Conjugates (ADCs)
5.1.3 Bispecific Antibodies (BsAbs)
5.1.4 Fc Engineered Antibodies
5.1.5 Antibody Fragments and Antibody-like Proteins
5.1.6 Biosimilar Antibody Products
5.1.7 Y-o-Y Growth Analysis, By Technology
5.1.8 Market Attractiveness Analysis, By Technology
5.1.9 Market Share Analysis, By Technology
5.2 Therapeutic Application
5.2.1 Introduction
5.2.2 Oncology
5.2.3 Autoimmune/Inflammatory Diseases
5.2.4 Y-o-Y Growth Analysis, By Therapeutic Application
5.2.5 Market Attractiveness Analysis, By Therapeutic Application
5.2.6 Market Share Analysis, By Therapeutic Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Technology
6.1.3.3 By Therapeutic Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Technology
6.1.4.3 By Therapeutic Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Technology
6.1.5.3 By Therapeutic Application
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Roche
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Seattle Genetics
8.3 Takeda
8.4 Dyax Corp.
8.5 Immunogen
8.6 Amgen, Inc.
8.7 Biogen
8.8 Kyowa Hakko Kirin Co., Ltd.
8.9 AstraZeneca
8.10 Pfizer, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Title | Price | Add To Cart |
© 2018 Market Data Forecast
All Rights Reserved.